| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
PC Biotin-PEG3-NHS ester is a linker molecule rather than a drug with a specific biological target. The biotin moiety allows affinity purification, and the photocleavable group enables the mild release of captured molecules. The NHS ester reacts with amines, and the PEG spacer provides hydrophilicity and flexibility.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1].
In vitro activity of PC Biotin-PEG3-NHS ester is not applicable as the compound is a chemical linker rather than a biologically active drug. Its utility lies in its ability to capture and release biomolecules in a light-controlled manner. |
| ln Vivo |
In vivo activity of PC Biotin-PEG3-NHS ester is not applicable as the compound is a chemical linker and not a therapeutic agent. Its applications are primarily in chemical biology and proteomics.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable for PC Biotin-PEG3-NHS ester, as the compound is a chemical linker rather than a pharmacologically active molecule. However, the compound can be characterized by its ability to capture and release proteins, which can be detected by mass spectrometry or Western blot analysis.
|
| Cell Assay |
Cell-based assays for PC Biotin-PEG3-NHS ester involve the use of the linker for the capture and release of proteins in cell lysates. The biotin moiety allows streptavidin-based enrichment, and the photocleavable group enables the release of captured proteins by UV light for analysis.
|
| Animal Protocol |
In vivo animal studies are not applicable for PC Biotin-PEG3-NHS ester as a standalone compound. However, the compound may be used in animal studies for the light-controlled release of drugs or other bioactive molecules.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of PC Biotin-PEG3-NHS ester itself are not applicable as it is a chemical linker. The compound contains a photocleavable group, a biotin moiety, a PEG3 spacer, and an NHS ester. For storage, the compound should be kept at -20°C under anhydrous conditions and protected from light.
|
| Toxicity/Toxicokinetics |
Toxicological data for PC Biotin-PEG3-NHS ester are limited. As a PEG-based linker, it is generally considered to have low toxicity and good biocompatibility. However, standard laboratory safety precautions should be followed when handling the compound. For research use only, not for therapeutic or human use.
|
| References |
[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
|
| Additional Infomation |
PC Biotin-PEG3-NHS ester (CAS# 2353409-93-3) is a heterobifunctional linker containing a photocleavable group, biotin, a PEG3 spacer, and an NHS ester. It is used for the light-controlled capture and release of biomolecules. The biotin moiety enables streptavidin-based enrichment, and the photocleavable group allows mild release upon UV exposure. The compound is for research use only.
|
| Molecular Formula |
C₃₆H₅₂N₆O₁₅S
|
|---|---|
| Molecular Weight |
840.89
|
| Exact Mass |
840.321
|
| CAS # |
2353409-93-3
|
| PubChem CID |
134827733
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
0.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
58
|
| Complexity |
1380
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC(C1=CC(=C(C=C1[N+](=O)[O-])OCCCC(=O)NCCOCCOCCOCCNC(=O)CCCC[C@H]2[C@@H]3[C@H](CS2)NC(=O)N3)OC)OC(=O)ON4C(=O)CCC4=O
|
| InChi Key |
WXAMRLAFOFNACR-VTJXTUSFSA-N
|
| InChi Code |
InChI=1S/C36H52N6O15S/c1-23(56-36(48)57-41-32(45)9-10-33(41)46)24-20-27(51-2)28(21-26(24)42(49)50)55-13-5-8-31(44)38-12-15-53-17-19-54-18-16-52-14-11-37-30(43)7-4-3-6-29-34-25(22-58-29)39-35(47)40-34/h20-21,23,25,29,34H,3-19,22H2,1-2H3,(H,37,43)(H,38,44)(H2,39,40,47)/t23?,25-,29-,34-/m0/s1
|
| Chemical Name |
1-[4-[4-[2-[2-[2-[2-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethoxy]ethoxy]ethoxy]ethylamino]-4-oxobutoxy]-5-methoxy-2-nitrophenyl]ethyl (2,5-dioxopyrrolidin-1-yl) carbonate
|
| Synonyms |
PC BiotinPEG3NHS ester; PC Biotin PEG3 NHS ester
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1892 mL | 5.9461 mL | 11.8922 mL | |
| 5 mM | 0.2378 mL | 1.1892 mL | 2.3784 mL | |
| 10 mM | 0.1189 mL | 0.5946 mL | 1.1892 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
